Latest From Alcon Inc.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Alcon Inc.
- Senior Management
David Endicott, CEO
Timothy C Stonesifer, SVP, CFO
Franck Leveiller, SVP, Head, Global R&D
Laurent Attias, Head, Global Corp. Dev. Strategy, BD&L, & M&A
Ed McGough, SVP, Global Mfctng. & Technical Operations
- Contact Info
Avenue Louis-Casaï 58
Cointrin-Geneva, TX CH-1216
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.